Halozyme Therapeutics (NASDAQ:HALO) Director Bernadette Connaughton Sells 1,625 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25. Following the completion of the sale, the director directly owned 43,669 shares of the company’s stock, valued at $2,891,324.49. The trade was a 3.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bernadette Connaughton also recently made the following trade(s):

• On Friday, May 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $66.28 on Wednesday. The company has a 50-day simple moving average of $66.24 and a 200-day simple moving average of $68.75. Halozyme Therapeutics, Inc. has a one year low of $51.06 and a one year high of $82.22. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The stock has a market capitalization of $7.86 billion, a price-to-earnings ratio of 23.84, a PEG ratio of 0.28 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same period in the prior year, the company earned $1.11 earnings per share. The business’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts predict that Halozyme Therapeutics, Inc. will post 7.6 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HALO. HC Wainwright upped their target price on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Morgan Stanley reduced their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.67.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC raised its holdings in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC raised its holdings in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares in the last quarter. Clearstead Advisors LLC raised its holdings in Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares in the last quarter. Harbour Investments Inc. raised its holdings in Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares in the last quarter. Finally, Penserra Capital Management LLC purchased a new position in Halozyme Therapeutics during the third quarter worth about $52,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.